Juno Therapeutics Inc. (NASDAQ:JUNO) moved up 6.07% and closed its last trading session at $25. This Medical Sector stock currently has the Market Capitalization of 2.79 Billion. The Average Volume for the stock is measured as 1.46 Million. The Stock has a 52-Week High of $57.82 and 52-Week Low of $22.37 following the dates, it touched its 52-Week High on Dec 1, 2015 and 52-Week Low on Feb 3, 2016. Currently, the Return on Assets value for the trailing twelve months is -16.5% with the Return on Equity and Return on Investment of -21% and -20.3% respectively. This firm currently has YTD (year to date) performance of -43.14 Percent which is not good. The Short Ratio for the stock is 8.25.
Juno Therapeutics Inc. (NASDAQ:JUNO) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-2.5. The TTM operating margin is 0 percent.
Juno Therapeutics Inc. (NASDAQ:JUNO) reports its Earnings on Tomorrow. The estimated EPS for the current quarter is said to be $-0.64. Following Earnings result, share price were UP 4 times out of last 7 Qtrs. The stock has reduced about -23.8% since it reported its last earnings. The Closing price of Juno Therapeutics Inc. (NASDAQ:JUNO) at Last Earnings was $30.92 as compared to the previous closing price of $22.72. The Predicted Move on the 7th day after Juno Therapeutics Inc. (NASDAQ:JUNO) will release its earnings at about 6%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Juno Therapeutics Inc. (NASDAQ:JUNO) beats earnings by 14%, The Stock Missed Earnings 4 times and has met earnings 2 times.
We will discuss the past Quarters Earnings below:
Juno Therapeutics Inc. (NASDAQ:JUNO) reported its previous quarter on 08/04/2016 where it reported the Actual Earnings of $-0.64. The Closing price before the company posted its earnings was $30.92. The Stock surged on the very next day of earnings and maintained its stock price at $31.46 by showing a % change of 1.75 percent from its previous closing price. The Next Day Volume after Earnings was reported as 2.09 Million. On the 7th day After Earnings Report, the stock hit its share price as $31.62 by showing 2.26% increase from the Stock price Before Earnings were reported.
On 05/09/2016, the stock reported the EPS of $-0.78 where Analysts were projecting the EPS to be $-0.52 showing a difference of $-0.26. Thus Surprise Factor was there with -50 percent. Before Earnings Announcement on 05/09/2016, the firm had its stock price of $38.49. And immediately on the next day after earnings announcement, the stock declined -0.08% and closed its trading session at $38.46. On 7th Day after earnings release, Juno Therapeutics Inc. (NASDAQ:JUNO) dropped to -0.86% from $38.49 to $38.16.
On 02/29/2016, Analysts were suspecting EPS of $-0.45/share where Juno Therapeutics Inc. (NASDAQ:JUNO) reported its Actual EPS of $-0.53. Thus showing a Surprise of -17.8 percent. The Closing Price of the stock before earnings was $35.17 while on the Next day the stock closed its trading session at $39.92 with a percentage change of 13.51% from the price of 35.17 before Earnings. The Stock Closing Price on the 7th day of earnings was $43.18.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The companys additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has collaboration agreements with Celgene Corporation, Editas Medicine, Inc., Fate Therapeutics, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.